Usefulness and limitations of serum and urine lysozyme levels in the classification of acute myeloid leukemia: An analysis of 208 cases
| Autor: | Bayard L. Powell, Carol W. Sexton, Julia M. Cruz, P. Nagesh Rao, David H. Buss, L. Douglas Case, Michael L. O'Connor, Mark J. Pettenati, Ralph D. Woodruff, Robert O. Rainer |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Male
Cancer Research Urine chemistry.chemical_compound Leukemia Promyelocytic Acute Leukemia Megakaryoblastic Acute hemic and lymphatic diseases Serum lysozyme medicine Humans Aged business.industry Myeloid leukemia Hematology Middle Aged medicine.disease Leukemia Myeloid Acute Leukemia Oncology chemistry Leukemia Myeloid Leukemia Monocytic Acute Immunology Acute myelomonocytic leukemia Female Muramidase Leukemia Erythroblastic Acute Lysozyme business Acute myeloblastic leukemia with maturation |
| Zdroj: | Leukemia Research. 20:467-472 |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/0145-2126(96)00001-x |
| Popis: | The revised French-American-British (FAB) classification system for acute myeloid leukemia (AML) recommends the determination of serum lysozyme (SL) or urine lysozyme (UL) levels as an aid in distinguishing acute myeloblastic leukemia with maturation (FAB M2) from acute myelomonocytic leukemia (M4). We reviewed retrospectively 208 cases of adult leukemia in which SL and/or UL were obtained. Elevated lysozyme levels were not found in any of the M0, M3, or M7 cases, but were increased (false positive) in three (14%) M1 cases, 18 (19%) M2 cases and one (20%) M6 case. Although a UL value in excess of 3x normal was found in most cases of AML M4 and M5, only five (11%) M4 cases and three (20%) M5 cases had SL elevations of this magnitude. Lysozyme levels need to be interpreted in conjunction with other parameters for FAB classification. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect